Status:
RECRUITING
Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Multiple Mieloma
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional, national, multicentre retrospective and prospective observational study aiming at assessing the efficacy of isatuximab-based regimens in RRMM patients with 1q21+ in a rea...
Detailed Description
This is a non-interventional, national, multicentre retrospective and prospective observational study aiming at assessing the efficacy of isatuximab-based regimens in RRMM patients with 1q21+ in a rea...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Signed Informed Consent form (whenever feasible)
- Diagnosis of RRMM prior exposed to \>1 lines of therapies including Isatuximab-based regimens
- Availability of FISH results, including 1q2, at diagnosis and/or at relapse
Exclusion
- None
Key Trial Info
Start Date :
December 27 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06874530
Start Date
December 27 2023
End Date
January 31 2026
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Azienda Ospedaliera-Universitaria di Bologna
Bologna, Italy, 40138